Special Populations and Immune Checkpoint Inhibitors: Are They Safe?

In this activity, three experts discuss how to incorporate immune checkpoint inhibitor therapy into the management of individuals classified as part of the "special population" of patients not generally included in clinical trials.

Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/946383?src=mkm_podcast_addon_946383